Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus GEOCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus GEOCILLIN.
AMPICILLIN AND SULBACTAM vs GEOCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Geocillin (carbenicillin indanyl sodium) is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible gram-negative and gram-positive bacteria.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250-500 mg orally every 6 hours.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
1.2 hours (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Primarily renal (70-80% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal (<5%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic